Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Semaglutide subcutaneous - Novo Nordisk

Next Previous
Drug Profile

Semaglutide subcutaneous - Novo Nordisk

Alternative Names: 9931; Kayshild; NN-9535; NN-9536; NN-9931; NNC-0113-0217; Ozempic; Wegovy

Latest Information Update: 20 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Developer Gilead Sciences; Novo Nordisk
  • Class Antidementias; Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Obesity therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus
  • Registered Liver cirrhosis; Renal failure
  • Preregistration Peripheral arterial disorders
  • Phase III Alzheimer's disease
  • Phase I Type 1 diabetes mellitus
  • No development reported Atherosclerosis; Non-alcoholic fatty liver disease

Most Recent Events

  • 17 Feb 2026 Registered for Obesity (In adults) in Norway, Iceland, Liechtenstein, European Union (SC)
  • 17 Feb 2026 Novo Nordisk plans to launch semaglutide subcutaneous in European Union, in 2026
  • 17 Feb 2026 Pooled efficacy and adverse events data from the phase III STEP UP and STEP UP T2D trials in Obesity released by Novo Nordisk

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top